6090.T Stock - Human Metabolome Technologies, Inc.
Unlock GoAI Insights for 6090.T
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.46B | $1.35B | $1.30B | $1.22B | $1.12B |
| Gross Profit | $922.00M | $869.33M | $859.75M | $840.00M | $806.02M |
| Gross Margin | 63.4% | 64.6% | 66.2% | 68.7% | 71.7% |
| Operating Income | $249.00M | $220.17M | $210.98M | $191.15M | $39.37M |
| Net Income | $256.00M | $243.25M | $285.76M | $267.79M | $58.21M |
| Net Margin | 17.6% | 18.1% | 22.0% | 21.9% | 5.2% |
| EPS | $43.59 | $41.14 | $48.39 | $45.39 | $9.87 |
Human Metabolome Technologies, Inc., biotechnology company, develops metabolomics technologies and solutions for drug discovery, diagnosis, and food production in Japan. The company provides metabolome analysis services; and global profiling, targeted assays, flux analysis, and lipidomics services. It also develops biomarkers, such as Phosphorylethanolamine, a biomarker for major depressive disorder and measured in blood plasma. The company offers solutions for cancer metabolism, metabolic flux analysis, infectious diseases, basic science, preclinical and clinical, food and nutrition, and microbiome applications. It has a collaboration with the Institute for Advanced Biosciences and Keio University for the development of metabolome analysis technology. The company was incorporated in 2003 and is based in Tsuruoka, Japan.
Visit WebsiteEarnings History & Surprises
6090.TEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 12, 2025 | — | $-17.11 | — | — |
Q3 2025 | Aug 8, 2025 | — | $-7.86 | — | — |
Q2 2025 | May 14, 2025 | — | $35.87 | — | — |
Q1 2025 | Feb 12, 2025 | — | $21.73 | — | — |
Q4 2024 | Nov 13, 2024 | — | $-5.99 | — | — |
Q3 2024 | Aug 9, 2024 | — | $2.48 | — | — |
Q2 2024 | May 15, 2024 | — | $26.63 | — | — |
Q1 2024 | Feb 14, 2024 | — | $18.47 | — | — |
Q4 2023 | Nov 10, 2023 | — | $-6.47 | — | — |
Q3 2023 | Aug 10, 2023 | — | $9.68 | — | — |
Q2 2023 | May 12, 2023 | — | $26.14 | — | — |
Q1 2023 | Feb 14, 2023 | — | $15.54 | — | — |
Q4 2022 | Nov 11, 2022 | — | $-2.98 | — | — |
Q3 2022 | Aug 10, 2022 | — | $-2.25 | — | — |
Q2 2022 | May 13, 2022 | — | $33.71 | — | — |
Q1 2022 | Feb 14, 2022 | — | $22.20 | — | — |
Q4 2021 | Nov 12, 2021 | — | $-8.28 | — | — |
Q3 2021 | Aug 13, 2021 | — | $-6.01 | — | — |
Q2 2021 | May 12, 2021 | — | $17.13 | — | — |
Q1 2021 | Feb 12, 2021 | — | $5.02 | — | — |
Latest News
Frequently Asked Questions about 6090.T
What is 6090.T's current stock price?
What is the analyst price target for 6090.T?
What sector is Human Metabolome Technologies, Inc. in?
What is 6090.T's market cap?
Does 6090.T pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to 6090.T for comparison